SGSweety Gupta

Sweety Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sweety Gupta has a total of 625 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    International survey on neoadjuvant treatments in anatomically resectable pancreatic adenocarcinoma (INSPIRA): a real-life snapshot

    by Chiara D'ALterio, Quirino Lai, Maria Lanzone, Roberto Valente, Matteo Fabbrici da Correggio, Immacolata Iannone, Alessandro Coppola, Salah Berkane, Tomas Koltai, Lucas McCormack, et al.

  • Nurse’s Knowledge of Morphine Use and Pain Management: Cross-sectional Study

    by Kusum Kumari, C Vasantha Kalyani, Sweety Gupta

    Background: Pain is a major cause of stress for people who are hospitalized. Research on Indian nurses’ knowledge of pain management is scarce. Objectives: The primary objective was to ascertain the nurses’ knowledge about pain management and morphine use. Secondary objectives included assessing the correlation of palliative care knowledge scores with demographic variables. Materials and Methods: This cross-sectional study was conducted at All India Institute of Medical Sciences, Rishikesh. There were 70 nursing officers involved who were working in chronic kidney disease (CKD) units, medical and surgical wards, and intensive care units, among other areas, and data collection was done via an online Google Form data sheet. Results: The mean age of the 70 participating nursing officers was 28.5 years; they were female, had 6 months to 2 years of experience (43, 61%), and had not completed any palliative care courses (49, 70%) or attended any sessions (49, 70%). The modified palliative care knowledge questionnaire was validated and found reliable (0.85). 72%, or 50 nurses, had a moderate degree of understanding about palliative care. Gender (0.009*), years of experience (0.000*), completion of palliative courses (0.013*), attendance at palliative care sessions (0.012*), family income (0.000*), and type of family (0.004*) showed a significant association with knowledge score at the 0.05 level of significance. Conclusion: The results of the study suggested that the nurses’ knowledge about pain management and morphine use was moderate. Inadequate palliative care education in the nursing program may result in a moderate degree of expertise. With the help of more research, courses that will enhance nursing students’ understanding and skills in higher education can also be created and assist nursing educators in modifying their curricula to enhance nurses’ performance in this area.

  • Open Access

    Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin for Muscle-Invasive Bladder Cancer: Real-World Feasibility and Safety in a Resource-Constrained Setting

    by Deepak Sundriyal, Sai Prasath, Harsha S. Prakash, Anusha Mruthyunjaya Swamy, Karthik Jayalingappa, Mayank Kapoor, Mahesh Koulagi, Deepa Joseph, Sweety Gupta, Parmod Kumar, et al.

    PURPOSE: Muscle-invasive bladder carcinoma (MIBC) poses major treatment challenges in low- and middle-income countries because of logistical and socioeconomic barriers limiting neoadjuvant chemotherapy (NAC) delivery. While dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) improves pathologic response and survival over gemcitabine-cisplatin, its multiday schedule reduces practicality. Accelerated MVAC (AMVAC), a single-day outpatient regimen, may offer a feasible alternative. This study evaluated the feasibility and safety of AMVAC in Indian patients with MIBC. METHODS: We conducted a single-arm feasibility study at the All India Institute of Medical Sciences, Rishikesh, India, between December 2021 and November 2024. Adults with stage II-III MIBC and cisplatin eligibility received 3-4 cycles of single-day AMVAC with pegfilgrastim support before radical cystectomy. Feasibility was defined as completion of ≥3 or 4 cycles within protocol-specified timeframes. Toxicities were graded using CTCAE v5.0, and outcomes were analyzed descriptively. RESULTS: Sixty patients were enrolled (mean age 55.2 ± 11.2 years; 90% male); 55 received neoadjuvant, and five adjuvant therapy. The mean number of chemotherapy cycles delivered was 3.87 ± 0.85. Feasibility outcomes were favorable, with 91.6% completing three and 76.6% completing four cycles within protocol timelines. Dose reductions for grade ≥3 toxicities were required in 13 patients (21.7%), whereas four patients discontinued treatment because of reduced creatinine clearance. Grade 3 adverse events occurred in 38.3%, most commonly anemia (16.7%), fatigue, and mucositis (13.3% each). Among neoadjuvant recipients undergoing cystectomy (n = 40), pathologic complete response (PCR) was achieved in 32.5% and pathologic downstaging was achieved in 55%. CONCLUSION: Single-day AMVAC is a feasible and tolerable NAC regimen in a resource-constrained setting, with encouraging PCR and manageable toxicity.

  • Open Access

    Clinical Presentation and Treatment Outcome of Multicentric Glioblastomas: A Case Series

    by Adil Ahmed Khan, Sanjay Sajeevan, Sweety Gupta, Deepa Joseph, Manoj Gupta, Aisha Mahmood

    Multicentric glioblastoma (MCG) is a rare and aggressive form of brain parenchymal malignancy, with limited evidence guiding its optimal management. A trimodality treatment approach—comprising surgery, radiotherapy, and chemotherapy—appears to offer better clinical outcomes compared with partial treatment or supportive care alone. This study aimed to shed light on possible treatment strategies in patients with MCG and their clinical outcomes. This is a retrospective case series of five patients diagnosed with MCG at our institution between January 2019 and December 2023. Patients were identified through a review of the institutional medical records department. Inclusion criteria were (1) histopathologically confirmed glioblastoma multiforme as per WHO classification, (2) radiological evidence of two or more spatially separate enhancing lesions in different brain regions with no connecting T2/FLAIR hyperintense signal, indicating absence of white matter tract dissemination or parenchymal continuity, consistent with MCG as per criteria, and (3) availability of complete clinical, radiological, and treatment data. All patients underwent pretreatment MRI with contrast, which was independently reviewed by two neuroradiologists. Surgical and oncological management decisions were made in multidisciplinary tumor board meetings. Molecular profiling, including methylguanine methyltransferase (MGMT) promoter methylation status and IDH1/IDH2 mutation status, was performed where available. Data collected included demographics, presenting symptoms, tumor locations, imaging findings, extent of surgical resection, adjuvant therapy, progression-free survival, and overall survival. Three patients underwent surgery, one underwent surgical biopsy, and one adult, being the exception—did not undergo any surgical intervention/biopsy. Three adults, except one adult and the pediatric patient, received radiation. All except one adult received temozolomide. The remaining adult patient who did not receive any treatment modality was a case of recurrent glioblastoma with multicentric disease, in a previously known case of solitary glioblastoma treated radically. This patient was kept on best supportive care. All the patients expired. Survival ranged from 3 to 14 months. The longest survivor (14 months) was an adult patient who underwent surgical resection followed by hypofractionated whole brain radiotherapy (30 Gy/10 fractions) and completed six cycles of adjuvant temozolomide. Patients receiving surgery followed by adjuvant therapy survived 11 to 14 months, whereas those receiving limited or no treatment had shorter survival (3–6 months). Although outcomes remain poor, patients receiving multimodal therapy appeared to have longer survival, although interpretation is limited by small sample size. Larger studies are required to validate these findings.

  • Open Access

    Urinary bladder involvement in rectal adenocarcinoma: An unusual site of metastasis

    by Pooja Doley, Sweety Gupta, Pooja Kalra, Harpreet Kaur, K. Akhila, Omkar Aapte, Ashok Singh, Deepa Joseph

    Colorectal cancer represents one of the most common malignancies worldwide, typically metastasizing to the liver, lungs, peritoneum, lymph nodes, and bones. Metastatic involvement of the urinary bladder, however, remains exceptionally rare. We report a case of a 52-year-old female with rectal adenocarcinoma who initially underwent neoadjuvant chemotherapy followed by concurrent chemoradiation. Subsequently, she developed persistent urinary tract infections and lower abdominal discomfort. Diagnostic cystoscopy and biopsy confirmed metastatic spread to the urinary bladder.

  • Patient-generated subjective global assessment and nutritional risk index for assessing nutritional decline during radical chemoradiotherapy in locally advanced head and neck cancer: a prospective single-center Indian study

    by Akhila K., Sweety Gupta, Pooja Doley, Roshni Balu, Harish Kumar, Manoj Gupta, Deepa Joseph

    Purpose Malnutrition is frequent in head and neck cancer patients and may worsen during chemoradiotherapy due to treatment-related toxicities. Early identification of nutritional risk is crucial to enhance treatment tolerance and outcomes. This study aimed to evaluate nutritional status of head and neck cancer patients using Patient-Generated Subjective Global Assessment (PG-SGA) and anthropometric parameters and to assess their association with acute toxicity and treatment response. Materials and methods This prospective observational study included 78 patients with locally advanced head and neck cancer treated with radical chemoradiotherapy. Baseline nutritional assessment included anthropometric parameters, biochemical markers, PG-SGA, and Nutritional Risk Index (NRI). Nutritional reassessment was done at treatment completion. Acute toxicities were graded using CTCAE v5.0 and treatment response was evaluated at 12 weeks using RECIST 1.1 criteria. Results The median age was 57 years and 91% of patients were male. At baseline, 85.9% of patients were well nourished according to PG-SGA, while NRI identified nutritional risk in 51.3% of patients. A significant association was observed between PG-SGA and NRI risk (p = 0.006). Baseline anthropometric parameters did not show significant association with nutritional status. However, serum albumin showed significant association with PG-SGA (p = 0.016) and NRI (p < 0.001). Post-treatment assessment demonstrated nutritional decline in 46.2% of patients. Pre-treatment PG-SGA did not correlate with acute toxicity or treatment response. However, severe dysphagia was significantly associated with post-treatment malnutrition (p < 0.001). Conclusion Nutritional deterioration is common during chemoradiotherapy in head and neck cancer patients. Patient-Generated Subjective Global Assessment, together with objective indices such as the Nutritional Risk Index, may help identify patients requiring timely nutritional intervention and swallowing support during treatment.

  • Open Access

    Patterns of treatment failure and survival outcomes following definitive intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma: a single centre experience

    by Abhishek Chakravarty, Sweety Gupta, Sumit Singh, Aviral Rastogi, Atokali Chophy, Ravindra Babu Shylaja Namitha, Ravi Roushan Kumar, Mayank Soni, Deepa M Joseph, Manoj Gupta

    Locally advanced head and neck squamous cell carcinoma (LA-HNSCC) continues to have suboptimal outcomes, with locoregional and distant failures remaining a significant cause of morbidity and mortality despite advances in radiotherapy techniques. This study evaluated failure patterns and survival outcomes following definitive intensity-modulated radiotherapy (IMRT) in LA-HNSCC. An ambispective analysis was conducted on LA-HNSCC patients who received definitive IMRT with weekly concurrent chemotherapy. Locoregional failures (both residual disease and new loco-regional recurrences) as well as distant metastases were identified. Patterns of failure were categorised as local, regional or distant. Kaplan-Meier method was used to assess survival outcomes and univariate and multivariate Cox regression models were utilised to identify factors associated with failures and survival. A total of 332 patients were analysed, with a median age of 58 years; 94% had stage III–IVB disease and 83.1% received concurrent chemotherapy. At a median follow-up of 10 months, failure was observed in 44.9% of patients. Local control rates at 3, 6, 12 and 24 months were 97.9%, 81.6%, 69.9% and 52.5%, respectively. Local failure was the most common failure pattern (33.4%), followed by regional (15.6%) and distant failure (9.3%). Primary tumour volume greater than 30 cc and an oral cavity primary site were independent predictors of local failure. Median disease-free survival and overall survival were 8.3 and 13.8 months, respectively. Despite the use of modern IMRT techniques, locoregional failure - particularly local failure - remains the predominant pattern of treatment failure in LA-HNSCC. Primary tumour volume is a critical determinant of outcome, highlighting the need for volumetric risk stratification and individualised treatment strategies to improve disease control in high-risk patients. However, the interpretation of survival outcomes should be considered in light of the wide range of follow-up duration in this cohort, which represents a limitation of the present study.

  • Outcomes of Hypofractionated Radiotherapy in Patients With Geriatric Head and Neck Cancer: Role of Comprehensive Geriatric Assessment

    by Mayank Soni, Sweety Gupta, Deepa M. Joseph, Sumit Singh, Manoj Gupta

    PURPOSE: Elderly patients with locally advanced head and neck squamous cell carcinoma (HNSCC) often present with frailty and multiple comorbidities, which reduce their tolerance to standard oncologic treatments. This study evaluates the outcomes of hypofractionated radiotherapy (RT) in frail elderly patients with HNSCC after geriatric assessment. METHODS: A prospective study was conducted among 154 elderly patients with nonmetastatic HNSCC (60 years and older) between October 2023 and October 2024. The G8 geriatric screening tool identified frail patients (G8 ≤ 14), who subsequently underwent a comprehensive geriatric assessment (CGA). Patients deemed unfit for radical treatment received hypofractionated RT. Treatment outcomes, toxicity, and survival were analyzed. RESULTS: Of 154 patients, 90 (58.45%) had G8 scores ≤14, indicating the need for CGA. Among them, 53 (58.88%) were unfit for definitive therapy and received hypofractionated RT. With a median follow-up of 3 months, the median overall survival (OS) was 6.5 months. At 3 months post-treatment, 39.6% of patients were alive, whereas 60.4% had died. There is a strong relation between G8 score and survival (regression coefficient [B] = 1.969, adjusted R 2 = 0.574, P < .001). With a median G8 score of 11, Kaplan-Meier analysis showed a significantly shorter median OS in patients with G8 ≤ 11 compared with those with G8 > 11 (3.66 v 11.10 months; P < .001). Among all domains of CGA, patients with normal nutritional status and low comorbidity index had significantly better OS (for Mini Nutritional Assessment, P < .001; for Charlson comorbidity index, P = .004). Treatment was well-tolerated, with minimal grade 3 toxicity. CONCLUSION: Hypofractionated RT is a feasible option for frail elderly patients with HNSCC, improving symptom control with manageable toxicity. G8 and CGA assessments facilitate personalized treatment, emphasizing quality of life over curative intent.


  • Epidemiology, Treatment Patterns, and Survival Outcomes in Patients With Uterine Cancer in a Real-World Setting in India

    by Shalini Bose, Kavita Khoiwal, Shalini Rajaram, Amrita Gaurav, Rajlaxmi Mundhra, Anupama Bahadur, Nilotpal Chowdhury, Ashok Singh, Sweety Gupta, Deepa Joseph, et al.

  • Phase II Open-Label Randomised Controlled Trial Comparing Oxaliplatin and Cisplatin Based Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Cancers

    by Y. Yanthan, L. Pandey, A. Pandey, R. Pasricha, D. Joseph, S. Gupta, A. Sehrawat, A. Dhyani, M. Gupta